Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,303.20
(
0.71%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.38
(
-0.27%
)
Bitcoin
74,280.60
(
0.46%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: zipjet post# 59208

Sunday, 02/17/2008 5:00:25 PM

Sunday, February 17, 2008 5:00:25 PM

Post# of 257253
>But for Copaxone to have ANY value for MNTA shareholders three things must happen. 1 - It must not be eliminated by a better drug/s. (Considering the marginal benefit of Copaxone, they could be displaced completely.) 2 - The company must stay viable. (That means mL or M118 needs to come through.) 3 - The company must stay independent - not bought out.<

I disagree on #3; clearly, a buyout offer for the whole company can incorporate an implicit valuation for the Copaxone program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now